scholarly article | Q13442814 |
P50 | author | Rainer Storb | Q19546769 |
Frederick R. Appelbaum | Q75025725 | ||
Wendy Leisenring | Q75026076 | ||
Hans Joachim Deeg | Q75039559 | ||
Mary E D Flowers | Q87982223 | ||
P2093 | author name string | Sanders JE | |
Martin PJ | |||
Nash RA | |||
Witherspoon RP | |||
Anasetti C | |||
Koc S | |||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | thalidomide | Q203174 |
P304 | page(s) | 3995-3996 | |
P577 | publication date | 2000-12-01 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Thalidomide for treatment of patients with chronic graft-versus-host disease | |
P478 | volume | 96 |
Q38778387 | A Canine Model of Chronic Graft-versus-Host Disease |
Q35737769 | A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease |
Q59810122 | A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801 |
Q33371639 | Chronic graft-versus-host disease: Pathogenesis and clinical management. |
Q33917187 | Current issues in chronic graft-versus-host disease |
Q37989375 | Cutaneous graft-versus-host disease--clinical considerations and management |
Q37268970 | Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. |
Q34077787 | Failure-free survival after initial systemic treatment of chronic graft-versus-host disease |
Q27012940 | Graft-versus-host disease: why have we not made more progress? |
Q34644980 | Have we made progress in the management of chronic graft-vs-host disease? |
Q46428638 | Ibrutinib for chronic graft-versus-host disease after failure of prior therapy |
Q39138108 | Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience |
Q26827651 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report |
Q86890944 | Phase-1/-2 study of pomalidomide in chronic GvHD |
Q38416371 | Prophylactic and therapeutic treatment of graft-versus-host disease in Japan |
Q36233448 | Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study |
Q35848933 | Rituximab for steroid-refractory chronic graft-versus-host disease |
Q38416376 | State-of-the-art acute and chronic GVHD treatment |
Q53681955 | Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. |
Q91830004 | Systemic Injection of Thalidomide Prevent and Attenuate Neuropathic Pain and Alleviate Neuroinflammatory Response in the Spinal Dorsal Horn |
Q34597832 | Thalidomide in cancer treatment: a potential role in the elderly? |
Q33361034 | Thalidomide-induced severe neutropenia during treatment of multiple myeloma |
Q38121762 | Therapeutic effects of thalidomide in hematologic disorders: a review |
Q37173479 | Therapy of chronic graft-versus-host disease |
Q37371836 | Treatment and management of graft-versus-host disease: improving response and survival |
Q26851433 | Treatment of chronic graft-versus-host disease in 2011 |
Q35524687 | Treatment of chronic graft-versus-host disease: Past, present and future |
Search more.